09-28-06
10/032286

Express Mail No. EV 809 954 766 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. 7,091,353 B2

Issued: August 15, 2006

Inventors: Robarge *et al.*

Atty Docket No.: 9516-048-999 (JD 501872-999047)

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The correction is described below and on the attached Form PTO-1050.

In column 177, line 20, the term "The" in the beginning of claim 5 should be replaced with "A".

In column 185, lines 40-50 (part of claim 14), the compound depicted in lines 40-50 (the fourth compound from the top) should be deleted as it is a duplicate of the compound depicted in the same column, lines 30-40 (the third compound from the top).

In column 186, lines 40-50 (also part of claim 14), the structure of the compound depicted in lines 40-50 (the fourth compound from the top) is incorrect. Specifically, the oxo (=O) group protruding from the substituents on 4-position should be "=S". Thus, the correct structure is as following:



In column 188, line 20, the dependency of claim 15 is incorrect. Specifically, claim 15 should depend from claim 5, rather than claim 1.

Marked-up revisions are shown in the attached Form PTO-1050.

Patentee respectfully points out that all of the mistakes are on the part of the Patent Office. For evidence, Patentee submits herewith a copy of a response filed May 6, 2005, with highlights in the relevant portions. Accordingly, an expedited issuance of Certificate of Correction is respectfully requested.

No fee is believed to be due for this Request. If any fees are due for the submission of this paper, however, please charge such fees, or any other required fees, to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: September 26, 2006

L0209

Hoon Choi (Limited Recog. No.)
JONES DAY

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200

Attachment

PRINTER'S TRIM LINE

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,091,353 B2
DATED : August 15, 2006
INVENTOR(S) : Robarge *et al.*

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 177, line 20, please revise Claim 5 as follows:
-- ~~The~~ A compound having the formula:--

In column 185, lines 40-50, please revise Claim 14 as follows, *i.e.*, delete the following structure:



--

In column 186, lines 40-50, please revise Claim 14 as follows:





--

In column 188, line 20, please revise Claim 15 as follows:
-- A compound of ~~claim 1~~ claim 5, which is:--

MAILING ADDRESS OF SENDER:
JONES DAY
222 East 41st Street
New York, NY 10017

CAJD-533356v1
FORM PTO 1050

PATENT NO. 7,091,353 B2

No. of add'l. copies
@ 30¢ perpage

==> _____

OCT 03 2006

Express Mail No. EV 809 954 766 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robarge *et al.*	Confirmation No.: 6358
Application No: 10/032,286	Group Art Unit: 1625
Filed: December 21, 2001	Examiner: C. Chang
For: ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF	Attorney Docket No.: 9516-048 (CAM 501872-999047)

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated April 15, 2005, Applicants submit the following amendments and remarks for the Examiner's consideration and entry into the records.

Amendments to the Claims are reflected on the listing of claims that begins on page 2 of this paper.

Remarks begin on page 11 of this paper.

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Canceled).

10. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1–C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1–C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;

R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;

each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–$C(O)O–R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

11. (Original) A compound of claim 10, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$, or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1$–$C_8)$alkyl, $(C_3$–$C_7)$cycloalkyl, $(C_2$–$C_8)$alkenyl, $(C_2$–$C_8)$alkynyl, benzyl, aryl, halogen, $(C_0$–$C_4)$alkyl–$(C_1$–$C_6)$heterocycloalkyl, $(C_0$–$C_4)$alkyl–$(C_2$–$C_5)$heteroaryl, $(C_0$–$C_8)$alkyl–$N(R^6)_2$, $(C_1$–$C_8)$alkyl–OR^5, $(C_1$–$C_8)$alkyl–$C(O)OR^5$, $(C_1$–$C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

12. (Original) A compound of claim 10, wherein R^1 is $C(O)R^3$.

13. (Original) A compound of claim 10, wherein R^1 is $C(O)OR^4$.

14. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1$–$C_8)$alkyl, $(C_3$–$C_7)$cycloalkyl, $(C_2$–$C_8)$alkenyl, $(C_2$–$C_8)$alkynyl, benzyl, aryl, $(C_0$–$C_4)$alkyl–$(C_1$–$C_6)$heterocycloalkyl, $(C_0$–$C_4)$alkyl–$(C_2$–$C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1$–$C_8)$alkyl–$N(R^6)_2$, $(C_1$–$C_8)$alkyl–OR^5, $(C_1$–$C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1$–$C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1$–$C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1$–$C_8)$alkyl, $(C_3$–$C_7)$cycloalkyl, $(C_2$–$C_8)$alkenyl, $(C_2$–$C_8)$alkynyl, benzyl, aryl, $(C_0$–$C_4)$alkyl–$(C_1$–$C_6)$heterocycloalkyl, $(C_0$–$C_4)$alkyl–$(C_2$–$C_5)$heteroaryl, $(C_0$–$C_8)$alkyl–$N(R^6)_2$, $(C_1$–$C_8)$alkyl–OR^5, $(C_1$–$C_8)$alkyl–$C(O)OR^5$, $(C_1$–$C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;
R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;
each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–$C(O)O–R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and
the * represents a chiral-carbon center.

15. (Original) A compound of claim 14, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$, or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, halogen, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

16. (Original) A compound of claim 14, wherein R^1 is $C(O)R^3$.

17. (Original) A compound of claim 14, wherein R^1 is $C(O)OR^4$.

18. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1–C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1–C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;

R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;

each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–$C(O)O–R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

19. (Original) A compound of claim 18, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$ or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, halogen, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

20. (Original) A compound of claim 18, wherein R^1 is $C(O)R^3$.

21. (Original) A compound of claim 18, wherein R^1 is $C(O)OR^4$.

22-100. (Canceled).

101. (Currently amended) A compound of claim 10, which is: ~~N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-duhydro-1H-isoindol-4-yl-methyl]-acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide; 1-tert-butyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-3,3-dimethylbutanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-3-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-furylcarboxamide; 2-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-thienylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoindolin-4yl]methyl}(ethylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}butanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}undecamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}2-methylpropanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclopentylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclohexylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(butylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(propylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}[(methylethylamino)]carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(octylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopropylamino)carboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(diethylamino)carboxamide.~~

(Claim 101 continued on next page)


or



102. (Currently amended) A compound of claim 10, which is: ~~[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid tert-butyl ester; 4-(aminomethyl)-2-(2,6-dioxo(3-Piperidyl))-isoindoline-1,3-dione; [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid ethyl ester; [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid benzyl ester; 2-(dimethylamino)-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}acetamide; ethyl 6-(3N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)hexanoate; 3-[(tert-butoxy)carbonylaminol-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; 3-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-methoxyacetamide; (N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)methyl acetate; ethyl 2-[N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)amino]acetate; 7-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}benzamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}phenylacetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(phenylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(benzylamino)carboxamide, 2-(2,6-dioxo-piperidin-3-yl)-4-{[(furan-2-ylmethyl)-amino-methyl}-isoindole-1,3-dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-isonicotinamide; 2-(2,6-dioxo(3-piperidyl))-4-({[(cyclohexylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-dioxo(3-piperidyl))-4-({[(ethylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-dioxo(3-piperidyl))-4-({[(propylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopentylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-~~

~~dioxoisoindolin-4-yl]methyl}(3-pyridylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}piperidylcarboxamide; or piperazine-1-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide.~~





103. (Currently amended) A compound of claim 14, which is: ~~N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}cyclopropylcarboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}(ethylamino)carboxamide.~~



104-105. (Canceled)

Remarks

Claims 10-21 and 101-103 are pending in this application. Claims 104-105 are canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation, or continuation-in-part applications. No new matter has been introduced.

Applicants appreciate the Examiner's recognition that claims 10-21 are allowable. Applicants respectfully submit that other pending claims are also allowable for the following reasons.

A. The Rejection Under 35 U.S.C. § 112, ¶1 Should Be Withdrawn

On pages 2-3 of the Office Action, claims 104-105 are rejected as allegedly failing to comply with the written description requirement for the reasons stated therein. Although Applicants respectfully disagree with the Examiner's contentions, claims 104-105 are canceled, without prejudice to Applicants' right to pursue the subject matter recited by them in related applications. In view of the cancellation of these claims, Applicants respectfully request that the rejection under 35 U.S.C. § 112 be withdrawn.

B. The Objection to Claims 101-103 Are Obviated

On page 3 of the Office Action, claims 101-103 are objected to as allegedly confusing. The Examiner recommends that structural delineation be made of record. To accommodate the Examiner's recommendation, claims 101-103 are amended to recite the chemical structures of individual species encompassed by claim 10 or 14.

Please note that the compound N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}undecamide (**I-78**), which is not encompassed by the genus recited by claim 10, but was inadvertently included in claim 101, is excluded from that claim. Furthermore, the compounds N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclohexylamino)carboxamide (**I-85**) and cyclopropyl-N-{[2-(3-methyl-2,6-dioxo(3-piperidyl))-1,3-dioxoisoindoln-4-yl]methyl}carboxamide (**I-139**), both of which are encompassed by the genus recited by claim 10, but were inadvertently excluded from claim 102, are added to that claim.

In view of these amendments, Applicants respectfully request that the objection to claims 101-103 be withdrawn.

No fee is believed to be due for this submission. However, should any fees be required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully Submitted,

Date: May 6, 2005



45,479
Max Bachrach Reg. No.

Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001
(202) 879-3939

Anthony M. Insogna (Reg. No. 35,203)
Jones Day
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200